TY - JOUR PY - 2021// TI - Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology JO - Crohn's and colitis 360 A1 - Karpin, J.E. A1 - Rodriguez, T.G. A1 - Traboulsi, C. A1 - Rai, V. A1 - Gibbons, R.D. A1 - Rubin, D.T. SP - EP - VL - 3 IS - 1 N2 - BACKGROUND: Depression and anxiety are comorbidities of inflammatory bowel disease (IBD), and it is now recommended to screen IBD patients for these conditions. We screened patients using a novel computerized adaptive testing technology and compared the screening results to measures of disease activity.

METHODS: Consecutive patients at our tertiary IBD clinic were asked to complete the validated CAT-MH survey (Adaptive Testing Technologies, Chicago, IL); we then reviewed disease and patient characteristics. Clinical remission status was determined based on clinical, laboratory, endoscopy, and imaging results. Statistical methods included Fisher exact test and Pearson chi-square tests to assess association. Univariable and multivariable analyses were performed.

RESULTS: We included 134 patients, of which 34 (25.3%) screened positive for depression and 18 (13.4%) screened positive for anxiety. We identified 19 (55.9%) and 10 (55.5%) patients who were previously undiagnosed for depression and anxiety, respectively. Patients in clinical remission were less likely to screen positive for depression (odds ratio 0.19; 95% confidence interval 0.07-0.50) and for anxiety (odds ratio 0.30; 95% confidence interval 0.10-0.91). Compared to patients with negative C-reactive protein values, patients with positive C-reactive protein were more likely to also screen positive for depression (P = 0.025) and anxiety (P = 0.15).

CONCLUSIONS: We demonstrate the utility of a novel testing technology for screening patients with IBD for depression and anxiety. We found a large number of patients with previously undiagnosed anxiety or depression and a significant positive association between clinically active IBD and these mental health conditions. This work supports and informs recommendations for mental health screening in the IBD population. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.

Language: en

LA - en SN - 2631-827X UR - http://dx.doi.org/10.1093/crocol/otaa095 ID - ref1 ER -